An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thrombosis and Haemostasis

• Publication date

  2010-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH10-03-0204PMID 20806114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

  2010cited by this paper
• Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?

  2009cited by this paper
• Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

  2008cited by this paper
• New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• New oral anticoagulants in atrial fibrillation.

  2007cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

  2005cited by this paper
• Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra®) anti‐Xa activity

  2004cited by this paper
• Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

  1992cited by this paper

• Impact of Drugs Used in Intensive Care on Routine Coagulation Testing

  2025cites this paper
• Predictive thresholds of peak and trough anti-Xa levels for bleeding risk in rivaroxaban-treated nonvalvular atrial fibrillation

  2025cites this paper
• Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)

  2025cites this paper
• The Role of Anti-Factor Xa Activity in the Management of Ecchymosis in Patients Receiving Rivaroxaban after Total Knee Arthroplasty

  2023cites this paper
• Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis

  2023cites this paper
• Viscoelastic Testing in the Management of Adult Patients on Mechanical Circulatory Support Devices with Focus on Extracorporeal Membrane Oxygenation.

  2022cites this paper
• The Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban: Results of the College of American Pathologists External Quality Assessment Program.

  2021cites this paper
• ROTEM Testing for Direct Oral Anticoagulants

  2021cites this paper
• Two Cases of Acute Direct Oral Anticoagulant Overdose Without Adverse Effect

  2021cites this paper
• Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)

  2021cites this paper
• ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study.

  2020cites this paper
• Assessment of low plasma concentrations of apixaban in the periprocedural setting

  2020cites this paper
• Advances in monitoring anticoagulant therapy.

  2019cites this paper
• Pharmacokinetic and pharmacodynamic drug monitoring of direct acting oral anticoagulants: Where do we stand?

  2019cites this paper
• Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma

  2019cites this paper
• Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants

  2019cites this paper
• International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study

  2019cites this paper
• The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban

  2019cites this paper
• Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban

  2018cites this paper
• Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians

  2018cites this paper
• Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants

  2018cites this paper
• The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis

  2018cites this paper
• Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging

  2018cites this paper
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

  2018cites this paper
• Betrixaban: Impact on Routine and Specific Coagulation Assays—A Practical Laboratory Guide

  2018cites this paper
• Management of the Trauma Patient on Direct Oral Anticoagulants

  2018cites this paper
• Laboratory Assessment of Direct Oral Anticoagulants

  2017cites this paper
• The prothrombotic state in atrial fibrillation : observations on fibrin clot structure and the relationship to renal dysfunction

  2017cites this paper
• Practical Use of Thromboelastometry in the Management of Perioperative Coagulopathy and Bleeding.

  2017cites this paper
• Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring

  2017cites this paper
• Monitoring of anticoagulant therapy in cancer patients with thrombosis and the usefulness of blood activation markers.

  2017cites this paper
• Possible Rivaroxaban Failure during the Postpartum Period: An Alternative Viewpoint

  2016cites this paper
• Direct Oral Anticoagulants: Correlation of Laboratory Monitoring With Safe Interventional Pain Procedures

  2016cites this paper
• Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics.

  2016cites this paper
• Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?

  2016cites this paper
• Antithrombotic therapy in patients with atrial fibrillation : the Tasmanian experience

  2016cites this paper
• Les anticoagulants oraux directs inhibiteurs du IIa et du Xa : surveillance biologique et gestion des accidents thérapeutiques

  2016cites this paper
• Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients.

  2016cites this paper
• Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless

  2016cites this paper
• Laboratory monitoring of rivaroxaban and assessment of its bleeding risk

  2016cites this paper
• Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

  2016cites this paper
• Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban

  2015cites this paper
• Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations

  2015cites this paper
• Coagulation assessment with the new generation of oral anticoagulants

  2015cites this paper
• Determinazione dei farmaci anticoagulanti orali diretti in regime di urgenza

  2015cites this paper
• Pharmacology and mechanisms of action of new oral anticoagulants

  2015cites this paper
• Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors

  2015cites this paper
• Edoxaban: Impact on routine and specific coagulation assays

  2015cites this paper
• Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

  2015cites this paper
• ヒーモスアイエル ヘパリン リキッド®を用いた抗Xa活性測定によるリバーロキサバン血中濃度モニタリングの臨床的意義

  2015cites this paper
• [Perioperative management of direct oral anticoagulant in emergency surgery and bleeding. Haemostasis monitoring and treatment].

  2015cites this paper
• Reversión de la anticoagulación en cirugía de urgencia

  2014cites this paper
• The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease

  2014cites this paper
• Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.

  2014cites this paper
• [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].

  2014cites this paper
• Running Title: Pharmacology of new oral anticoagulants

  2014cites this paper
• [Hemorrhagic stroke and new oral anticoagulants].

  2014cites this paper
• Measurement of rivaroxaban and apixaban in serum samples of patients

  2014cites this paper
• Nuevos anticoagulantes y anestesia regional

  2014cites this paper
• Pharmacology and laboratory testing of the oral Xa inhibitors.

  2014cites this paper
• A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?

  2014cites this paper
• Pharmacologie des anti-Xa et mécanismes d’action

  2014cites this paper
• Potential use of NOACs in developing countries: pros and cons

  2014cites this paper
• Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral Anticoagulants

  2013cites this paper
• Which test to use to measure the anticoagulant effect of rivaroxaban: the anti‐factor Xa assay

  2013cites this paper
• Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

  2013cites this paper
• Monitoring plasma levels of factor Xa inhibitors: how, why and when?

  2013cites this paper
• Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants

  2013cites this paper
• Laboratory assessment of rivaroxaban: a review

  2013cites this paper
• Anticoagulant Treatment With Rivaroxaban in Severe Protein

  2013cites this paper
• The laboratory and the new oral anticoagulants.

  2013cites this paper
• Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency

  2013cites this paper
• Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide

  2013cites this paper
• The laboratory and the direct oral anticoagulants.

  2013cites this paper
• Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

  2013cites this paper
• Clinical management of rivaroxaban-treated patients

  2013cites this paper
• Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test

  2013cites this paper
• Rivaroxaban: Practical Considerations for Ensuring Safety and Efficacy

  2013cites this paper
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting

  2013cites this paper
• Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants

  2013cites this paper
• Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban

  2013cites this paper
• Coagulation Assays in Patients with New Oral Anticoagulants (NOACs): Why? When?

  2013cites this paper
• Los nuevos anticoagulantes orales en la fibrilación auricular: preguntas y respuestas para el urgenciólogo

  2013cites this paper
• Étude ARISTOTLE : comparaison entre l’apixaban et la warfarine pour la prévention des AVC chez les patients atteints de fibrillation auriculaire

  2013cites this paper
• Influence des nouveaux anticoagulants sur les examens de la coagulation Intérêt en clinique

  2013cites this paper
• Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?

  2013cites this paper
• Neue orale Antikoagulanzien (NOAK) in der Intensivmedizin

  2013cites this paper
• Novel anticoagulants and laboratory testing

  2013cites this paper
• Managing bleeding in anticoagulated patients in the emergency care setting.

  2013cites this paper
• Perioperatives Management der Antikoagulation mit Rivaroxaban – Konsensus einer interdisziplinären Arbeitsgruppe

  2012cites this paper
• Laboratory tests and the new oral anticoagulants.

  2012cites this paper
• Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation.

  2012cites this paper
• Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL

  2012cites this paper
• [Pharmacology of the new oral anticoagulants].

  2012cites this paper
• New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation

  2012cites this paper
• Impact of dabigatran on a large panel of routine or specific coagulation assays

  2012cites this paper
• Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.

  2012cites this paper
• Anticoagulant therapy for patients with ischaemic stroke

  2012cites this paper
• Rivaroxaban in der Prävention und Therapie thromboembolischer Erkrankungen

  2012cites this paper
• In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

  2012cites this paper